Trevi Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on November 10, 2021. The filing serves to announce the Company's financial results for the quarter ended September 30, 2021. The Company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "TRVI".
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report explicitly states that the detailed financial results are contained within a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the body of this Form 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document functions solely as a notification of the results announcement rather than a detailed financial statement.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within its text. It notes that the information provided under Item 2.02 and Exhibit 99.1 is deemed "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting its liability and incorporation into other filings unless expressly referenced.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 financial figures including cash position and net loss.
- Verify the Company's cash runway and burn rate as disclosed in the referenced press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full announcement.
- Check for any forward-looking statements or guidance provided in the press release that are not present in this 8-K summary.